...
search icon
crbu-img

Caribou Biosciences Inc, Common Stock

CRBU

NSQ

$0.8743

+$0.01

(1.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$84.02M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
652.98K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.36
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.66 L
$4.39 H
$0.8743

About Caribou Biosciences Inc, Common Stock

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCRBUSectorS&P500
1-Week Return13.92%-0.29%3.55%
1-Month Return-18.29%-7.65%-5.72%
3-Month Return-43.59%-4.64%-9.82%
6-Month Return-53.98%-12.35%-9.51%
1-Year Return-79.81%-4.34%1.26%
3-Year Return-88.99%-3.64%19.2%
5-Year Return-94.64%43.5%90.39%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue12.36M9.60M13.85M34.48M9.99M[{"date":"2020-12-31","value":35.85,"profit":true},{"date":"2021-12-31","value":27.84,"profit":true},{"date":"2022-12-31","value":40.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":28.99,"profit":true}]
Cost of Revenue34.42M984.00K3.64M112.08M-[{"date":"2020-12-31","value":30.72,"profit":true},{"date":"2021-12-31","value":0.88,"profit":true},{"date":"2022-12-31","value":3.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(22.06M)8.61M10.21M(77.60M)9.99M[{"date":"2020-12-31","value":-216.1,"profit":false},{"date":"2021-12-31","value":84.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-760.02,"profit":false},{"date":"2024-12-31","value":97.88,"profit":true}]
Gross Margin(178.50%)89.75%73.71%(225.07%)100.00%[{"date":"2020-12-31","value":-178.5,"profit":false},{"date":"2021-12-31","value":89.75,"profit":true},{"date":"2022-12-31","value":73.71,"profit":true},{"date":"2023-12-31","value":-225.07,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses48.48M76.58M120.25M150.54M176.61M[{"date":"2020-12-31","value":27.45,"profit":true},{"date":"2021-12-31","value":43.36,"profit":true},{"date":"2022-12-31","value":68.09,"profit":true},{"date":"2023-12-31","value":85.24,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(36.12M)(66.98M)(106.40M)(116.06M)(166.62M)[{"date":"2020-12-31","value":-3612400000,"profit":false},{"date":"2021-12-31","value":-6697900000,"profit":false},{"date":"2022-12-31","value":-10639900000,"profit":false},{"date":"2023-12-31","value":-11605900000,"profit":false},{"date":"2024-12-31","value":-16661600000,"profit":false}]
Total Non-Operating Income/Expense213.00K517.00K---[{"date":"2020-12-31","value":41.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(36.13M)(66.60M)(99.35M)(101.88M)(149.11M)[{"date":"2020-12-31","value":-3612700000,"profit":false},{"date":"2021-12-31","value":-6660200000,"profit":false},{"date":"2022-12-31","value":-9935100000,"profit":false},{"date":"2023-12-31","value":-10187700000,"profit":false},{"date":"2024-12-31","value":-14911400000,"profit":false}]
Income Taxes(1.82M)321.00K70.00K193.00K(9.00K)[{"date":"2020-12-31","value":-566.67,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":21.81,"profit":true},{"date":"2023-12-31","value":60.12,"profit":true},{"date":"2024-12-31","value":-2.8,"profit":false}]
Income After Taxes(34.31M)(66.92M)---[{"date":"2020-12-31","value":-3430800000,"profit":false},{"date":"2021-12-31","value":-6692300000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(34.31M)(66.92M)(99.42M)(94.55M)(149.10M)[{"date":"2020-12-31","value":-3430800000,"profit":false},{"date":"2021-12-31","value":-6692300000,"profit":false},{"date":"2022-12-31","value":-9942100000,"profit":false},{"date":"2023-12-31","value":-9455400000,"profit":false},{"date":"2024-12-31","value":-14910500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(34.31M)(66.92M)(99.42M)(102.07M)(149.10M)[{"date":"2020-12-31","value":-3430800000,"profit":false},{"date":"2021-12-31","value":-6692300000,"profit":false},{"date":"2022-12-31","value":-9942100000,"profit":false},{"date":"2023-12-31","value":-10207000000,"profit":false},{"date":"2024-12-31","value":-14910500000,"profit":false}]
EPS (Diluted)(1.39)(3.25)(1.64)(1.45)(1.66)[{"date":"2020-12-31","value":-138.52,"profit":false},{"date":"2021-12-31","value":-325.26,"profit":false},{"date":"2022-12-31","value":-164,"profit":false},{"date":"2023-12-31","value":-145,"profit":false},{"date":"2024-12-31","value":-166.44,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CRBU
Cash Ratio 6.84
Current Ratio 7.16

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRBU
ROA (LTM) -27.18%
ROE (LTM) -47.99%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRBU
Debt Ratio Lower is generally better. Negative is bad. 0.19
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.81

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRBU
Trailing PE NM
Forward PE NM
P/S (TTM) 8.41
P/B 0.32
Price/FCF NM
EV/R 112.73
EV/Ebitda NM

FAQs

What is Caribou Biosciences Inc share price today?

Caribou Biosciences Inc (CRBU) share price today is $0.8743

Can Indians buy Caribou Biosciences Inc shares?

Yes, Indians can buy shares of Caribou Biosciences Inc (CRBU) on Vested. To buy Caribou Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRBU stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Caribou Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Caribou Biosciences Inc (CRBU) via the Vested app. You can start investing in Caribou Biosciences Inc (CRBU) with a minimum investment of $1.

How to invest in Caribou Biosciences Inc shares from India?

You can invest in shares of Caribou Biosciences Inc (CRBU) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRBU stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Caribou Biosciences Inc shares
What is Caribou Biosciences Inc 52-week high and low stock price?

The 52-week high price of Caribou Biosciences Inc (CRBU) is $4.39. The 52-week low price of Caribou Biosciences Inc (CRBU) is $0.66.

What is Caribou Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Caribou Biosciences Inc (CRBU) is 0.32

What is the Market Cap of Caribou Biosciences Inc?

The market capitalization of Caribou Biosciences Inc (CRBU) is $84.02M

What is Caribou Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Caribou Biosciences Inc is CRBU

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top